NAGENiagen Bioscience IncHealthcare · Biotechnologyas of 2026-09-16
Horizon

Issued 2026-09-16 at $3.00 · now $3.00 (2026-09-16, +0.0% since)

Based on its own history, a month from the 2026-09-16 close, NAGE has typically landed between $2.21 and $4.18 — a range of −26.4% to +39.3% from the issuance price $3.00.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

4,543 overlapping 1 month windows · 2008-06-252026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.756.1%, ≈1,408 obs).

The cone is anchored at the 2026-09-16 issuance close ($3.00) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where NAGE has typically landed a month from the 2026-09-16 close of $3 — the range is history, not a prediction.

$2.21worst · -26.4%$4.18best · +39.3%
  • now $3 (+0.0%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $2.88 (-4.1%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $2.6$3.15
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $2.21$4.18
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 4,543 windows spanning 2008-06-25 to 2026-09-16. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2008-09-19−92.0%−92.0%+0.0%
2008-09-22−92.0%−92.0%+0.0%
2008-09-09−89.8%−89.8%+0.0%
3 best
2008-11-10+610.0%+0.0%+610.0%
2008-12-01+445.5%+0.0%+545.5%
2008-11-28+445.5%+0.0%+545.5%

4,543 overlapping windows · 2008-06-252026-09-16 · not cherry-picked

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~19 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.
Jan
61%
+6.0%
n=18
Feb
61%
+12.3%
n=18
Mar
33%
−1.9%
n=18
Apr
56%
+12.0%
n=18
May
56%
+3.9%
n=18
Jun
50%
−0.1%
n=18
Jul
47%
+1.5%
n=19
Aug
37%
−2.0%
n=19
Sep
32%
−6.2%
n=19
Oct
28%
−7.3%
n=18
Nov
56%
+14.0%
n=18
Dec
33%
+19.7%
n=18

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$10$32025-11-14: 2 insider purchases, $46K — Pamir Ozan …2025-11: 2 open-market purchases, $46K↑ buys↓ salesofficer Pamir Ozan — Purchase on 2025-11-14, filed 3 days after the tradeofficer Pamir Ozan — Purchase on 2025-11-14, filed 3 days after the trade
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling
2025-11-14Pamir OzanofficerPurchase4,465 @ $6.81$30K+153.6% of holding−8.7%−56.4%7,372Form 4 · filed 3 days after the trade
2025-11-14Pamir OzanofficerPurchase2,220 @ $6.85$15Kownership Δ n/a−8.7%−56.4%2,220Form 4 · filed 3 days after the trade

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

24 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

DatePersonRoleActionSharesOwned afterFiling
2026-06-30Pamir OzanofficerAward / grant4,25511,627Form 4
2026-06-30Lopez Carlos LuisofficerAward / grant2,3144,565Form 4
2026-06-30Fried Robert NdirectorAward / grant1,1061,060,087Form 4
2026-06-24Ng Wang Yu GarydirectorAward / grant31,74631,746Form 4
2026-06-24YU Wing Tak WendydirectorAward / grant31,74631,746Form 4
2026-06-24Patrick KristindirectorAward / grant31,74631,746Form 4
2026-06-24Shahbazi HameddirectorAward / grant31,74631,746Form 4
2026-06-24Rubin Steven DdirectorAward / grant31,74631,746Form 4
2026-06-24Cohen AnndirectorAward / grant31,74631,746Form 4
2026-06-24Jaksch Frank L JrdirectorAward / grant31,74631,746Form 4
2026-04-24Fried Robert NdirectorOption exercise20,0001,058,981Form 4
2026-04-24Fried Robert NdirectorOption exercise20,0000Form 4
2026-02-19Lopez Carlos LuisofficerAward / grant41,42041,420Form 4
2026-02-19Fried Robert NdirectorAward / grant503,937503,937Form 4
2026-02-19Pamir OzanofficerAward / grant62,13162,131Form 4
2025-06-24Shahbazi HameddirectorAward / grant20,00020,000Form 4
2025-06-24YU Wing Tak WendydirectorAward / grant20,00020,000Form 4
2025-06-24Patrick KristindirectorAward / grant20,00020,000Form 4
2025-06-24Jaksch Frank L JrdirectorAward / grant20,00020,000Form 4
2025-06-24Cohen AnndirectorAward / grant20,00020,000Form 4
2025-06-24Ng Wang Yu GarydirectorAward / grant20,00020,000Form 4
2025-06-24Rubin Steven DdirectorAward / grant20,00020,000Form 4
2025-04-09Fried Robert NdirectorOption exercise66,6671,038,981Form 4
2025-04-09Fried Robert NdirectorOption exercise66,6670Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.